JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
On Friday, Kepler Cheuvreux analysts initiated coverage on Galderma Group AG (GALD:SW) stock with a Buy rating. The analysts set a price target of CHF137.00, highlighting the company’s promising growth prospects driven by two significant product launches and increasing profit margins.
The analysts noted that Galderma’s product Nemluvio, which is already gaining traction in treating prurigo nodularis and atopic dermatitis, is expected to significantly boost sales and profitability. Another product, Relfydess, is enhancing the company’s aesthetics portfolio with its longer duration and favorable economic attributes, supporting global market share growth and potential margin improvements.
Kepler Cheuvreux emphasized Galderma’s continued strong performance in injectable aesthetics and the resilience added by its skincare division. The company’s platform, restructured since its separation from Nestlé in 2019, is now positioned for scalability.
According to the analysts, Galderma effectively combines the scientific potential of biopharma with the pricing power and capital efficiency of consumer health. This strategic positioning reduces the company’s exposure to structural risks typically associated with either sector.
Despite acknowledging that Galderma’s stock is not inexpensive, the analysts believe it merits further re-rating due to its robust growth trajectory and strategic advantages.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.